NCT04354545Recruiting
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 15 Apr 2020
- Start date
- 1 Apr 2021
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Glaucoma
- NCT number
- NCT04354545
What you commit to
- Study type: Observational
- Planned participants: 75
- From 1 Apr 2021 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- current use of topical steroids
- incisional ocular surgery within 6 months
Other illness
- History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
Other
- current use of topical cyclosporine
Who the study is looking for
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Doheny Eye Center UCLA Coordinator of this site? Confirm its status | Fountain Valley | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.